Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy

Introduction: Risankizumab and secukinumab are effective treatment options for patients with moderate to severe psoriasis. Objective: We sought to estimate the efficacy and the cost per responder of risankizumab and secukinumab by comparing these two drugs in a real-life setting. Methods:.A mul...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Federico Pirro, Giacomo Caldarola, Nicoletta Bernardini, Maria Grazia Celeste, Annunziata Dattola, Eleonora De Luca, Marco Galluzzo, Domenico Giordano, Chiara Izzi, Giulia Maretti, Lorenzo Marcelli, Roberto Ravasio, Antonio Giovanni Richetta, Nevena Skroza, Marina Talamonti, Arianna Zangrilli, Luca Bianchi, Giovanni Pellacani, Severino Persechino, Concetta Potenza, Ketty Peris, Clara De Simone
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Mattioli1885 2025-01-01
coleção:	Dermatology Practical & Conceptual
Assuntos:	efficacy cost per responder risankizumab secukinumab psoriasis
Acesso em linha:	https://dpcj.org/index.php/dpc/article/view/4838
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!